Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Immutep and keeping the price target at $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Immutep’s strategic advancements and potential for growth. A significant driver is the recent collaboration and licensing agreement with Dr. Reddy’s, which not only validates Immutep’s lead asset, eftilagimod alpha (efti), but also expands its reach into international markets outside of North America, Europe, Japan, and Greater China. This deal provides Immutep with a substantial upfront payment and potential milestone earnings, offering non-dilutive capital that strengthens its financial position.
Moreover, Immutep retains global manufacturing rights, ensuring long-term revenue opportunities while leveraging Dr. Reddy’s extensive market presence. This strategic partnership complements ongoing clinical trials, such as the pivotal P3 TACTI-004 study in metastatic non-small cell lung cancer and the P2/3 AIPAC-003 program in metastatic breast cancer. These developments underscore the potential for significant value creation, supporting McCarthy’s optimistic outlook on the stock.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, SCYNEXIS, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -8.6% and a 36.35% success rate on recommended stocks.